VNRX: Two (2) licensing agreements signed during September, specifically for Nu.Q NETs research related to APS in humans with Werfen S.A. and for Nu.Q Discover services with Hologic Diagen...
VolitionRX Limited (VNRX)
NASDAQ:AMEX Investor Relations:
ir.volitionrx.com
Company Research
Source: Yahoo! Finance
VolitionRx's (NYSE:VNRX) announcements of two significant licensing agreements in September 2025 represent the materialization of a key priority that was described during the second quarter 2025 conference call in August. During the call, CEO Cameron Reynolds relayed that the company was in confidential discussions with over 10 companies and that the negotiations at each company were at various stages, ranging from due diligence to contract finalization. He specifically indicated that the company was very close to signing its first human Nu.Q NETs licensing deal , which he anticipated would occur during the third quarter. This milestone for the company was achieved in early September Both licensing agreements announced in September represent tangible progress toward management's emphasized goal of securing multiple licensing agreements. These two agreements represent only the initial announcements of what management anticipates will be a stream of multiple licensing deals through t
Show less
Read more
Impact Snapshot
Event Time:
VNRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VNRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VNRX alerts
High impacting VolitionRX Limited news events
Weekly update
A roundup of the hottest topics
VNRX
News
- VolitionRx (NYSE:VNRX) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $5.00 price target on the stock.MarketBeat
- VolitionRx Limited Announces Inclusion of its Nu.Q® NETs Assay as Innovative Biomarker in France's Real-World Evaluation of Early Detection of SepsisPR Newswire
- VolitionRx (NYSE:VNRX) had its "hold" rating reaffirmed by analysts at Maxim Group.MarketBeat
- VolitionRx (NYSE:VNRX) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $5.00 price target on the stock.MarketBeat
- VolitionRx Limited Announces the First Sale of the Nu.Q® Cancer Assays for Clinical Certification in Preparation for Routine Clinical Use [Yahoo! Finance]Yahoo! Finance
VNRX
Earnings
- 11/13/25 - Miss
VNRX
Sec Filings
- 11/17/25 - Form 4
- 11/14/25 - Form SCHEDULE
- 11/10/25 - Form 8-K/A
- VNRX's page on the SEC website